Inactive Instrument

Invitrocue Limited

Equities

IVQ

AU000000IVQ8

Invitrocue Limited Announces Invivocue Pte Ltd Completes Development of its Ace-2 Humanized Immune Mice Platform

September 23, 2020 at 10:21 pm EDT

Leading Life Sciences company Invitrocue Limited announced the Group, through its subsidiary company Invivocue Pte Ltd. has completed development of its ACE-2 Humanized Immune Mice platform which enables in-vivo testing of drug and vaccine candidates against SARS-CoV-2 virus or COVID19 disease in lab mice. In addition to be used for the Covid 19 virus, the HiMice can also be used for other virus or disease that targets the Angiotensin-Converting Enzyme 2 receptor. The research is funded by Singapore government research arm A STAR with Dr Qingfeng Chen leading the research as part of the Hi-Mice Licensing agreement signed with Accelerate Technologies Pte Ltd, an affiliate of A STAR, on 3 June 2019, which allows Invivocue to make Enhancement to Hi-Mice.

Latest news about Invitrocue Limited

Invitrocue Limited Announces Resignation of Directors	21-02-26	CI
Invitrocue Limited Announces Invivocue Pte Ltd Completes Development of its Ace-2 Humanized Immune Mice Platform	20-09-23	CI
Invitrocue Limited Enters into Partnership with Pangaea Oncology SA	20-09-23	CI
Invitrocue Limited Announces the Appointment of Chow Yee Koh as an Executive Director of the Company as Replacement of Geoffrey Thomas	20-03-02	CI
Invitrocue Limited, Invitrocue Pte Ltd Sign Binding Memorandum of Understanding with Felipe Eduardo De Almeida E Silva for the Establishment of a Joint Venture Company Called Invitrocue Brazil	20-02-10	CI
Invitrocue Limited Announces Joint Venture with ChinaLink Limited	19-12-06	CI
Invitrocue Limited announced that it expects to receive $10.25 million in funding	19-12-05	CI
INVITROCUE (HONG KONG) LTD announced that it expects to receive $1 million in funding from Invitrocue Limited and other investor	19-12-05	CI
Invitrocue Limited Announces the Cessation of Kit Wei Lui as Director, Effective from 15 October 2019	19-10-17	CI
Invitrocue Limited Announces the Cessation of Hanry Yu as Director, Effective from 15 October 2019	19-10-17	CI
Invitrocue Limited Announces Cancellation of General Meeting	19-10-15	CI
Hanry Yu, Kit Wei Lui and Ee Ting Ng Tender Their Resignation as Directors of Invitrocue Limited	19-10-15	CI
Declaration of Voting Results by Invitrocue Limited	19-10-10	CI
Invitrocue Limited Reports Earnings Results for the Full Year Ended June 30, 2019	19-10-02	CI
Invitrocue Limited announced that it has received $0.75 million in funding	19-09-30	CI
Invitrocue Limited Announces the Establishment of Laboratory Facility in Hong Kong	19-09-27	CI
Invitrocue Limited Announces Clinical Validation Study Underway for Its Onco-Pdotm Test with Klinikum Rechts Der Isar Der Technischen Universität München, Comprehensive Cancer Center Munich, Germany	19-09-24	CI
Invitrocue Limited Announces Directorate Changes	19-09-18	CI
Invitrocue Gives Notice of General Meeting to Shareholders	19-09-17	CI
Boon Sing Fang Responds to Notice of Meeting	19-09-16	CI
Invitrocue Limited Announces the Removal of Boon Sing Fang from the Office of Director	19-09-10	CI
Invitrocue Limited Gives a Notice of General Meeting	19-09-10	CI
Invitrocue Limited Appoints Geoffrey Thomas as Non-Executive Director	19-09-09	CI
Hanry Yu Requisitions General Meeting to Remove Director at Invitrocue Limited	19-09-06	CI
Boon Sing Fang Requisitions General Meeting to Remove Directors at Invitrocue Limited	19-09-06	CI

Chart Invitrocue Limited

Duration

Period

More charts

Company Profile

Invitrocue Limited is engaged in research and experimental development on biotechnology, life and medical science. The Company offers a three dimension (3D) cell-based scaffolding technology, which mimics a human for Tropical Diseases to investigate the lifecycle of Plasmodium cynomolgi (monkey malaria) and helps in evaluating new drug targets to malaria infection using in vitro hepatocyte culture systems. It is engaged in developing non-small cell lung cancer organoids and for drug testing programs using approved drugs. It is also engaged in range of activities, including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging, while providing access to industry networks. It also offers an in vitro screening of experimental drug compounds for anti-leishmanial activity. It intends to develop an in vitro 3D perfused liver model to expedite and facilitate new application notes in infectious liver diseases.

Sector

More about the company